Fig. 2From: High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatmentLog rank survival analysis showed no difference between patients with high and low SLFN11 expressing tumors in the cohort as a whole (Log rank P = 0.411)Back to article page